{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:05:55Z","timestamp":1740175555746,"version":"3.37.3"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T00:00:00Z","timestamp":1449792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bolet\u00edn M\u00e9dico del Hospital Infantil de M\u00e9xico"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.bmhimx.2015.11.007","type":"journal-article","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T22:18:31Z","timestamp":1456352311000},"page":"31-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recent advances in the risk factors, diagnosis and management of Epstein-Barr virus post-transplant lymphoproliferative disease"],"prefix":"10.1016","volume":"73","author":[{"given":"Paibel","family":"Aguayo-Hiraldo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reuben","family":"Arasaratnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayne H.","family":"Rouce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmhimx.2015.11.007_bib0280","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/imt.15.7","article-title":"Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors","volume":"7","author":"Smith","year":"2015","journal-title":"Immunotherapy."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0285","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.4448","article-title":"The role of Epstein\u2013Barr virus in epithelial malignancies","volume":"235","author":"Tsao","year":"2015","journal-title":"J Pathol."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0290","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat EBV lymphoproliferation","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0295","first-page":"e2009032","article-title":"EBV and HIV-related lymphoma","volume":"1","author":"Bibas","year":"2009","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0300","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4132\/KoreanJPathol.2013.47.2.137","article-title":"EBV-positive T\/NK-cell lymphoproliferative disease of childhood","volume":"47","author":"Hong","year":"2013","journal-title":"Korean J Pathol."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0305","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3324\/haematol.2013.087338","article-title":"Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation","volume":"99","author":"Uhlin","year":"2014","journal-title":"Haematologica."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0310","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12185-014-1599-6","article-title":"Three different histological subtypes of Epstein-Barr virus-negative post-transplant lymphoproliferative disorder in a patient with hepatitis C infection","volume":"100","author":"Kobayashi","year":"2014","journal-title":"Int J Hematol."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0315","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-9-38","article-title":"Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010","volume":"9","author":"Khan","year":"2014","journal-title":"Infect Agent Cancer."},{"year":"2008","series-title":"World Health Organization classification of tumors of haematopoietic and lymphoid tissues","author":"Swerdlow","key":"10.1016\/j.bmhimx.2015.11.007_bib0320"},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0325","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/bmt.2013.96","article-title":"EBV-induced post-transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT","volume":"49","author":"Rasche","year":"2014","journal-title":"Bone Marrow Transplantation."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0330","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","article-title":"Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0335","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5114\/ceji.2015.50845","article-title":"Successful treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disease with central nervous system involvement following allogeneic haematopoietic stem cell transplantation\u2014a case study","volume":"40","author":"Wr\u00f3blewska","year":"2015","journal-title":"Cent Eur J Immunol."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0340","unstructured":"European Conference on Infections in Leukemia. ECIL 4; 2011."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0345","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MOH.0000000000000083","article-title":"Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant","volume":"21","author":"Rouce","year":"2014","journal-title":"Curr Opin Hematol."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0350","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/cid\/cit391","volume":"57","author":"Styczynski","year":"2013","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0355","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00000478-199803000-00004","article-title":"Epstein-Barr virus infections in children after transplantation of the small intestine","volume":"22","author":"Finn","year":"1998","journal-title":"Am J Surg Pathol."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0360","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1111\/j.1600-6143.2012.04197.x","article-title":"Pediatric Heart Transplant Study. A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients","volume":"12","author":"Chinnock","year":"2012","journal-title":"Am J Transplant."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0365","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1097\/00007890-199711270-00011","article-title":"Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus","volume":"64","author":"Sokal","year":"1997","journal-title":"Transplantation."},{"issue":"Suppl 1","key":"10.1016\/j.bmhimx.2015.11.007_bib0370","first-page":"8","volume":"14","year":"2014","journal-title":"Am J Transplant."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0375","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ajh.23452","article-title":"Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation","volume":"88","author":"Liu","year":"2013","journal-title":"Am J Hematol."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0380","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.transproceed.2010.01.077","article-title":"Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience","volume":"42","author":"Pinho-Apezzato","year":"2010","journal-title":"Transplant Proc."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0385","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1182\/blood-2003-12-4287","article-title":"Prompt versus preemptive intervention for EBV lymphoproliferative disease","volume":"103","author":"Wagner","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2015.02.002","article-title":"Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey","volume":"21","author":"San-Juan","year":"2015","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0395","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2015.08.007","article-title":"Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment","volume":"369","author":"Petrara","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0400","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.386","article-title":"Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections and Leukemia","volume":"43","author":"Styczynski","year":"2009","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0405","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/978-3-642-56352-2_12","article-title":"Low-dose chemotherapy for children with post-transplant lymphoproliferative disease","volume":"159","author":"Gross","year":"2002","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0410","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1111\/j.1600-6143.2012.04206.x","article-title":"Low-dose chemotherapy and rituximab for post-transplant lymphoproliferative disease (PTLD): a Children's Oncology Gr**oup Report","volume":"12","author":"Gross","year":"2012","journal-title":"Am J Transplant."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0415","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/bmt.2014.298","article-title":"Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab","volume":"50","author":"Garc\u00eda-Cadenas","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0420","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","article-title":"T-cell therapy in the treatment of post-transplant lymphoproliferative disease","volume":"9","author":"Bollard","year":"2012","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0425","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1399-3062.2009.00411.x","article-title":"Outcome of treatment of Epstein-Barr virus related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases","volume":"11","author":"Styczynski","year":"2009","journal-title":"Transpl Infect Dis."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0430","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0435","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0440","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0445","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0450","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0455","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0460","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0465","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","article-title":"Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)","volume":"108","author":"Savoldo","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0470","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0475","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/mt.2014.48","article-title":"Systemic inflammatory response syndrome after administration of unmodified T lymphocytes","volume":"22","author":"Papadopoulou","year":"2014","journal-title":"Mol Ther."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0480","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0485","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-041610-134208","article-title":"Familial and aquired hemophagocytic lymphohistiocytosis","volume":"63","author":"Janka","year":"2012","journal-title":"Annu Rev Med."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0490","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/tid.12287","article-title":"Treatment of rare co-ocurrence of Epstein-Barr virus-driven post-transplant lymphoproliferative disorder and hemophagocytic lymphohystiocytosis after allogeneic stem cell transplantation","volume":"16","author":"Weber","year":"2014","journal-title":"Transpl Infect Dis."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0495","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/petr.12558","article-title":"Prompt diagnosis and management of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder and hemophagocytosis: a dreaded complication in a post-liver transplant child","volume":"19","author":"Jha","year":"2015","journal-title":"Pediatr Transplant."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0500","doi-asserted-by":"crossref","first-page":"e0136752","DOI":"10.1371\/journal.pone.0136752","article-title":"Initial hyperleukocytosis and neutrophilia in nasopharyngeal carcinoma: incidence and prognostic impact","volume":"10","author":"Su","year":"2015","journal-title":"PLoS ONE."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0505","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.538","article-title":"Early life exposures to infectious agents and later cancer developement","author":"Vedham","year":"2015","journal-title":"Cancer Med."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0510","doi-asserted-by":"crossref","first-page":"847","DOI":"10.6004\/jnccn.2015.0102","article-title":"National Comprehensive Cancer Network. Head and Neck Cancers, Version 1.2015","volume":"13","author":"Pfister","year":"2015","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0515","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/mt.2013.242","article-title":"Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma","volume":"22","author":"Chia","year":"2014","journal-title":"Mol Ther."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0520","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","article-title":"Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes","volume":"23","author":"Comoli","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0525","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/CJI.0b013e3181f3cbf4","article-title":"Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma","volume":"33","author":"Louis","year":"2010","journal-title":"J Immunother."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0530","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2217\/imt.13.22","article-title":"Targeting EBV's Achilles\u2019 heel with antigen-specific T cells","volume":"5","author":"Kalra","year":"2015","journal-title":"Immunotherapy."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0535","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2007-05-091280","article-title":"Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer","volume":"110","author":"Bollard","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0540","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/mt.2015.91","article-title":"Long-term outcome of extranodal NK\/T cell lymphoma patients treated with postremission therapy using EBV LMP1 and LMP2a-specific CTLs","volume":"23","author":"Cho","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0545","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bbmt.2010.07.008","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of 2001 evidence-based review","volume":"17","author":"Oliansky","year":"2011","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.bmhimx.2015.11.007_bib0550","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2008.20.0857","article-title":"Lymphoma after solid organ transplantation: risk, response to therapy, and suvival at a transplantation center","volume":"27","author":"Knight","year":"2009","journal-title":"J Clin Oncol."}],"container-title":["Bolet\u00edn M\u00e9dico del Hospital Infantil de M\u00e9xico"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1665114615002403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1665114615002403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T15:46:01Z","timestamp":1539877561000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665114615002403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1665114615002403"],"URL":"https:\/\/doi.org\/10.1016\/j.bmhimx.2015.11.007","relation":{},"ISSN":["1665-1146"],"issn-type":[{"type":"print","value":"1665-1146"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the risk factors, diagnosis and management of Epstein-Barr virus post-transplant lymphoproliferative disease","name":"articletitle","label":"Article Title"},{"value":"Bolet\u00edn M\u00e9dico del Hospital Infantil de M\u00e9xico","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.bmhimx.2015.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Hospital Infantil de M\u00e9xico Federico G\u00f3mez. Published by Masson Doyma M\u00e9xico S.A.","name":"copyright","label":"Copyright"}]}}